ID

21965

Beschreibung

Two Cycles of PAD Combination by AHCT in MM; ODM derived from: https://clinicaltrials.gov/show/NCT01370434

Link

https://clinicaltrials.gov/show/NCT01370434

Stichworte

  1. 10.05.17 10.05.17 -
Hochgeladen am

10. Mai 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Multiple Myeloma NCT01370434

Eligibility Multiple Myeloma NCT01370434

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with newly diagnosed symptomatic mm (see appendix i)
Beschreibung

Multiple Myeloma Symptomatic

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0026764
UMLS CUI [1,2]
C0231220
patients should be eligible for ahct.
Beschreibung

Patient eligible Transplantation of autologous hematopoietic stem cell

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1548635
UMLS CUI [1,3]
C1831743
patients should have measurable serum or urine paraprotein.
Beschreibung

Serum paraprotein measurement | Urine paraprotein measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0585639
UMLS CUI [2]
C0585640
the performance status of the patients should be 70 or over by karnofsky performance scale
Beschreibung

Karnofsky Performance Status

Datentyp

boolean

Alias
UMLS CUI [1]
C0206065
adequate hepatic and renal function: serum bilirubin < 1.5 x the upper limit of normal (uln), serum alanine aminotransferase (alt)/aspartate aminotransaminase (ast) values < 2.5 x uln, serum creatinine < 1.5 x uln
Beschreibung

Liver function | Renal function | Serum total bilirubin measurement | Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Creatinine measurement, serum

Datentyp

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
UMLS CUI [3]
C1278039
UMLS CUI [4]
C0201836
UMLS CUI [5]
C0201899
UMLS CUI [6]
C0201976
adequate cardiac function: ejection fraction > 40% by echocardiogram or radionuclide heart scan
Beschreibung

Cardiac function | Cardiac ejection fraction Echocardiography | Cardiac ejection fraction Radionuclide Imaging Heart

Datentyp

boolean

Alias
UMLS CUI [1]
C0232164
UMLS CUI [2,1]
C0232174
UMLS CUI [2,2]
C0013516
UMLS CUI [3,1]
C0232174
UMLS CUI [3,2]
C0034606
UMLS CUI [3,3]
C0018787
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior chemotherapy for myeloma except 4 days of dexamethasone up to 40 mg per day or localized radiotherapy or plasmapheresis for the treatment of clinically significant hyperviscosity syndrome
Beschreibung

Chemotherapy Multiple Myeloma | Dexamethasone U/day | Therapeutic radiology procedure Localized | Plasmapheresis Hyperviscosity syndrome

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0026764
UMLS CUI [2,1]
C0011777
UMLS CUI [2,2]
C0456683
UMLS CUI [3,1]
C1522449
UMLS CUI [3,2]
C0392752
UMLS CUI [4,1]
C0032134
UMLS CUI [4,2]
C0221030
have a peripheral neuropathy of grade 2 or more within 14 days of enrollment.
Beschreibung

Peripheral Neuropathy CTCAE Grades

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
significant infection
Beschreibung

Communicable Disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0009450

Ähnliche Modelle

Eligibility Multiple Myeloma NCT01370434

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Myeloma Symptomatic
Item
patients with newly diagnosed symptomatic mm (see appendix i)
boolean
C0026764 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
Patient eligible Transplantation of autologous hematopoietic stem cell
Item
patients should be eligible for ahct.
boolean
C0030705 (UMLS CUI [1,1])
C1548635 (UMLS CUI [1,2])
C1831743 (UMLS CUI [1,3])
Serum paraprotein measurement | Urine paraprotein measurement
Item
patients should have measurable serum or urine paraprotein.
boolean
C0585639 (UMLS CUI [1])
C0585640 (UMLS CUI [2])
Karnofsky Performance Status
Item
the performance status of the patients should be 70 or over by karnofsky performance scale
boolean
C0206065 (UMLS CUI [1])
Liver function | Renal function | Serum total bilirubin measurement | Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Creatinine measurement, serum
Item
adequate hepatic and renal function: serum bilirubin < 1.5 x the upper limit of normal (uln), serum alanine aminotransferase (alt)/aspartate aminotransaminase (ast) values < 2.5 x uln, serum creatinine < 1.5 x uln
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0201899 (UMLS CUI [5])
C0201976 (UMLS CUI [6])
Cardiac function | Cardiac ejection fraction Echocardiography | Cardiac ejection fraction Radionuclide Imaging Heart
Item
adequate cardiac function: ejection fraction > 40% by echocardiogram or radionuclide heart scan
boolean
C0232164 (UMLS CUI [1])
C0232174 (UMLS CUI [2,1])
C0013516 (UMLS CUI [2,2])
C0232174 (UMLS CUI [3,1])
C0034606 (UMLS CUI [3,2])
C0018787 (UMLS CUI [3,3])
Item Group
C0680251 (UMLS CUI)
Chemotherapy Multiple Myeloma | Dexamethasone U/day | Therapeutic radiology procedure Localized | Plasmapheresis Hyperviscosity syndrome
Item
prior chemotherapy for myeloma except 4 days of dexamethasone up to 40 mg per day or localized radiotherapy or plasmapheresis for the treatment of clinically significant hyperviscosity syndrome
boolean
C0392920 (UMLS CUI [1,1])
C0026764 (UMLS CUI [1,2])
C0011777 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C1522449 (UMLS CUI [3,1])
C0392752 (UMLS CUI [3,2])
C0032134 (UMLS CUI [4,1])
C0221030 (UMLS CUI [4,2])
Peripheral Neuropathy CTCAE Grades
Item
have a peripheral neuropathy of grade 2 or more within 14 days of enrollment.
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Communicable Disease
Item
significant infection
boolean
C0009450 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video